Drugs / HFB200603
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05789069 | May 2023 → Dec 2026 expected | colorectal cancer, gastric cancer, melanoma, non-small cell lung carcinoma +1 | HiFiBiO Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HFB200603 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05789069 ↗ |
| Route | Intravenous | “Participants will be administered HFB200603 at dose levels 1-4 as an intravenous infusion” NCT05789069 ↗ |
| Target | BTLA | “Anti-BTLA Antibody” NCT05789069 ↗ |